Comparative Pharmacology
Head-to-head clinical analysis: PHYRAGO versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHYRAGO versus PROMETHAZINE HYDROCHLORIDE.
PHYRAGO vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PHYRAGO is a monoclonal antibody that targets and neutralizes the activity of a specific inflammatory cytokine, thereby inhibiting downstream signaling pathways involved in immune-mediated inflammation.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
200 mg orally twice daily with food.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours in adults; may be prolonged in hepatic impairment (up to 15 hours).
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <5% of dose; fecal elimination of metabolites accounts for ~90%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic